In this article
The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk
and Eli Lilly
’s blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding in bulk.
If that proposal is finalized, the exclusion would likely limit the mass compounding — or the making of custom, often cheaper alternatives — of those medicines unless they appear on the FDA’s drug shortage list. The agency said it will consider public comments, which can be submitted until late June, before making a final decision.
